JP2009542592A5 - - Google Patents

Download PDF

Info

Publication number
JP2009542592A5
JP2009542592A5 JP2009517037A JP2009517037A JP2009542592A5 JP 2009542592 A5 JP2009542592 A5 JP 2009542592A5 JP 2009517037 A JP2009517037 A JP 2009517037A JP 2009517037 A JP2009517037 A JP 2009517037A JP 2009542592 A5 JP2009542592 A5 JP 2009542592A5
Authority
JP
Japan
Prior art keywords
fusion protein
pharmaceutical composition
receptor
immunoglobulin
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009517037A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009542592A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2007/005904 external-priority patent/WO2008003473A2/en
Publication of JP2009542592A publication Critical patent/JP2009542592A/ja
Publication of JP2009542592A5 publication Critical patent/JP2009542592A5/ja
Pending legal-status Critical Current

Links

JP2009517037A 2006-07-06 2007-07-04 Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法 Pending JP2009542592A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81874106P 2006-07-06 2006-07-06
US85613906P 2006-11-02 2006-11-02
PCT/EP2007/005904 WO2008003473A2 (en) 2006-07-06 2007-07-04 Compositions and methods for enhancing the efficacy of il-2 mediated immune responses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012271134A Division JP2013100297A (ja) 2006-07-06 2012-12-12 Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法

Publications (2)

Publication Number Publication Date
JP2009542592A JP2009542592A (ja) 2009-12-03
JP2009542592A5 true JP2009542592A5 (https=) 2013-02-07

Family

ID=38616357

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2009517037A Pending JP2009542592A (ja) 2006-07-06 2007-07-04 Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法
JP2012271134A Pending JP2013100297A (ja) 2006-07-06 2012-12-12 Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012271134A Pending JP2013100297A (ja) 2006-07-06 2012-12-12 Ｉｌ−２媒介性免疫応答の有効性を高める組成物および方法

Country Status (7)

Country Link
US (2) US20080025947A1 (https=)
EP (1) EP2038417A2 (https=)
JP (2) JP2009542592A (https=)
AU (1) AU2007271398B2 (https=)
CA (1) CA2656700A1 (https=)
IL (1) IL196282A (https=)
WO (1) WO2008003473A2 (https=)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US20050202538A1 (en) * 1999-11-12 2005-09-15 Merck Patent Gmbh Fc-erythropoietin fusion protein with improved pharmacokinetics
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PT1383785E (pt) * 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
PT1454138E (pt) 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
CA2551915C (en) * 2003-12-30 2015-06-23 Merck Patent Gesellschaft Mit Beschraenkter Haftung Il-7 fusion proteins
JP2008504008A (ja) * 2003-12-31 2008-02-14 メルク　パテント　ゲゼルシャフト　ミット　ベシュレンクテル　ハフトング 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質
US7670595B2 (en) * 2004-06-28 2010-03-02 Merck Patent Gmbh Fc-interferon-beta fusion proteins
US20070104689A1 (en) * 2005-09-27 2007-05-10 Merck Patent Gmbh Compositions and methods for treating tumors presenting survivin antigens
US20090176654A1 (en) * 2007-08-10 2009-07-09 Protelix, Inc. Universal fibronectin type III binding-domain libraries
US8680019B2 (en) * 2007-08-10 2014-03-25 Protelica, Inc. Universal fibronectin Type III binding-domain libraries
US8470966B2 (en) 2007-08-10 2013-06-25 Protelica, Inc. Universal fibronectin type III binding-domain libraries
MX2011007647A (es) 2009-01-21 2011-09-01 Amgen Inc Composiciones y metodos para el tratamiento de enfermedades inflamatorias y autoinmunes.
EP2421896A1 (en) * 2009-04-22 2012-02-29 Merck Patent GmbH Antibody fusion proteins with modified fcrn binding sites
CU23734A1 (es) * 2009-11-27 2011-11-15 Centro Inmunologia Molecular Polipéptidos inmunomoduladores derivados de la il-2 con actividad antagonista de esta citocina útiles en la terapia del cáncer y enfermedades infecciosas crónicas
CU23923B1 (es) * 2010-11-12 2013-07-31 Ct De Inmunología Molecular Polipéptidos derivados de la il-2 con actividad agonista
MX2013009151A (es) * 2011-02-10 2013-08-29 Roche Glycart Ag Inmunoterapia mejorada.
HUE029139T2 (hu) * 2011-02-10 2017-02-28 Roche Glycart Ag Mutáns interleukin-2 polipeptidek
EA201892619A1 (ru) 2011-04-29 2019-04-30 Роше Гликарт Аг Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
EP2723380B1 (en) * 2011-06-24 2019-08-21 Stephen D. Gillies Light chain immunoglobulin fusion proteins and methods of use thereof
US9844582B2 (en) 2012-05-22 2017-12-19 Massachusetts Institute Of Technology Synergistic tumor treatment with extended-PK IL-2 and therapeutic agents
AR092044A1 (es) * 2012-08-07 2015-03-18 Roche Glycart Ag Inmunoterapia mejorada
US20140044675A1 (en) 2012-08-10 2014-02-13 Roche Glycart Ag Interleukin-2 fusion proteins and uses thereof
US10519242B2 (en) 2013-03-15 2019-12-31 Xencor, Inc. Targeting regulatory T cells with heterodimeric proteins
EP2970486B1 (en) 2013-03-15 2018-05-16 Xencor, Inc. Modulation of t cells with bispecific antibodies and fc fusions
EP3049114B1 (en) 2013-09-27 2021-11-10 Massachusetts Institute of Technology Carrier-free biologically-active protein nanostructures
KR102042246B1 (ko) 2014-02-06 2019-11-28 에프. 호프만-라 로슈 아게 인터류킨-2 융합 단백질 및 이의 용도
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
GB2538666A (en) * 2014-07-21 2016-11-23 Delinia Inc Molecules that selectively activate regulatory T cells for the treatment of autoimmune diseases
US20170224777A1 (en) * 2014-08-12 2017-08-10 Massachusetts Institute Of Technology Synergistic tumor treatment with il-2, a therapeutic antibody, and a cancer vaccine
US11371066B2 (en) 2015-07-13 2022-06-28 Modular Genetics, Inc. Generation of acyl alcohols
PT3328894T (pt) 2015-08-06 2019-02-13 Agency Science Tech & Res Anticorpos de cadeia comum gama/il2rbeta
KR102739782B1 (ko) * 2015-09-11 2024-12-09 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 생물학적으로 관련된 직교 사이토카인/수용체 쌍
US10888603B2 (en) 2016-02-12 2021-01-12 The Board Of Trustees Of The Leland Stanford Junior University Methods of treating cancer cells expressing tumor-associated integrins
KR102379464B1 (ko) 2016-06-20 2022-03-29 키맵 리미티드 항-pd-l1 항체
US9567399B1 (en) 2016-06-20 2017-02-14 Kymab Limited Antibodies and immunocytokines
AU2017335771A1 (en) 2016-09-28 2019-02-28 Musc Foundation For Research Development Antibodies that bind interleukin-2 and uses thereof
EP3534947A1 (en) 2016-11-03 2019-09-11 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses & methods
US11077172B2 (en) 2016-11-08 2021-08-03 Delinia, Inc. IL-2 variants for the treatment of psoriasis
BR112019018915A2 (pt) 2017-03-15 2020-04-14 Pandion Therapeutics Inc imunotolerância direcionada
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
JPWO2018199318A1 (ja) * 2017-04-28 2020-03-12 国立大学法人高知大学 抗ｇｐｃ−１抗体
BR112019024556A2 (pt) 2017-05-24 2020-06-23 Novartis Ag Proteínas enxertadas com citocina de anticorpo e métodos para uso no tratamento de câncer
JP2020521452A (ja) 2017-05-24 2020-07-27 パンディオン・セラピューティクス・インコーポレイテッド 標的化免疫寛容
WO2019028419A1 (en) 2017-08-03 2019-02-07 Synthorx, Inc. CYTOKINE CONJUGATES FOR THE TREATMENT OF PROLIFERATIVE AND INFECTIOUS DISEASES
USRE50550E1 (en) 2017-12-06 2025-08-26 Pandion Operations, Inc. IL-2 muteins and uses thereof
US10174091B1 (en) 2017-12-06 2019-01-08 Pandion Therapeutics, Inc. IL-2 muteins
US10946068B2 (en) 2017-12-06 2021-03-16 Pandion Operations, Inc. IL-2 muteins and uses thereof
CA3084262A1 (en) * 2017-12-06 2019-06-13 The Board Of Trustees Of The Leland Stanford Junior University Engineered proteins to enhance sensitivity of a cell to il-2
KR102909650B1 (ko) 2018-03-13 2026-01-08 터스크 테라퓨틱스 리미티드 종양 특이적 세포 고갈에 대한 항-cd25
KR102721494B1 (ko) * 2018-04-17 2024-10-24 국립암센터 고갈성 항 cd4 단일클론항체를 포함하는 항암 t 세포치료제 보조용 조성물 및 이의 용도
US12459980B2 (en) 2018-07-25 2025-11-04 AskGene Pharma, Inc. IL-21 prodrugs and methods of use thereof
US11492384B2 (en) * 2018-09-17 2022-11-08 Gi Innovation, Inc. Fusion protein comprising IL-2 protein and CD80 protein, and use thereof
WO2020154032A1 (en) 2019-01-23 2020-07-30 Massachusetts Institute Of Technology Combination immunotherapy dosing regimen for immune checkpoint blockade
KR20260039812A (ko) 2019-02-06 2026-03-20 신톡스, 인크. Il-2 콘쥬게이트 및 이의 사용 방법
CN111944036B (zh) * 2019-05-14 2024-09-06 上海盖浦生物科技有限公司 一种增殖免疫细胞的突变体蛋白
US20220241375A1 (en) 2019-05-20 2022-08-04 Cytune Pharma Il-2/il-15r beta gamma agonist dosing regimens for treating cancer or infectious diseases
WO2020236875A1 (en) 2019-05-20 2020-11-26 Pandion Therapeutics, Inc. Madcam targeted immunotolerance
KR20220020879A (ko) 2019-06-12 2022-02-21 에스크진 파마, 아이엔씨. 새로운 il-15 프로드럭 및 이를 사용하는 방법
CN114555633A (zh) * 2019-06-26 2022-05-27 约翰霍普金斯大学 用于靶向扩增免疫效应细胞的方法和材料
CA3147757A1 (en) 2019-07-26 2021-02-04 Visterra, Inc. Interleukin-2 agents and uses thereof
KR20220044534A (ko) * 2019-08-13 2022-04-08 엘피스 바이오파마슈티컬즈 조작된 인터류킨-2 수용체 베타 효능제
AU2020401371A1 (en) 2019-12-13 2022-07-21 Synthekine, Inc. IL-2 orthologs and methods of use
MX2022007712A (es) * 2019-12-17 2022-09-26 Amgen Inc Agonista doble de interleucina-2/receptor de tnf para uso en terapia.
AU2020406083A1 (en) * 2019-12-17 2022-06-16 Boehringer Ingelheim International Gmbh Bifunctional molecules comprising an IL-7 variant
CN114478743A (zh) 2019-12-17 2022-05-13 北京志道生物科技有限公司 白介素-2衍生物
WO2021142471A1 (en) 2020-01-11 2021-07-15 AskGene Pharma, Inc. Novel masked cytokines and methods of use thereof
US11981715B2 (en) 2020-02-21 2024-05-14 Pandion Operations, Inc. Tissue targeted immunotolerance with a CD39 effector
AR121891A1 (es) 2020-04-22 2022-07-20 Merck Sharp & Dohme CONJUGADOS DE INTERLEUCINA 2 HUMANA SESGADOS AL DÍMERO DEL RECEPTOR DE INTERLEUCINA 2 bgᶜ Y CONJUGADOS CON UN POLÍMERO HIDROSOLUBLE NO PEPTÍDICO
EP4232069A1 (en) 2020-10-26 2023-08-30 Cytune Pharma Il-2/il-15rbetagamma agonist for treating squamous cell carcinoma
MX2023004880A (es) 2020-10-26 2023-05-11 Cytune Pharma AGONISTA DE IL-2/IL-15RßY PARA EL TRATAMIENTO DE CÁNCER DE PIEL QUE NO ES MELANOMA.
EP4255466A1 (en) 2020-12-04 2023-10-11 Visterra, Inc. Methods of using interleukin-2 agents
KR20230129441A (ko) * 2020-12-17 2023-09-08 오제 이뮈노테라프틱스 이기능성 항-pd1/il-7 분자
AU2022253351A1 (en) * 2021-04-09 2023-10-12 Boehringer Ingelheim International Gmbh New scaffold for bifunctional molecules with improved properties
EP4362969A4 (en) * 2021-06-30 2025-05-07 The Regents of University of California CHANGE IN CYTOKINE SPECIFICITY BY BINDING VALENCE
US20240350589A1 (en) 2021-08-13 2024-10-24 Cytune Pharma Il-2/il-15rbetagamma agonist combination with antibody-drug conjugates for treating cancer
JP2024536840A (ja) * 2021-09-26 2024-10-08 ウーシー バイオロジクス アイルランド リミテッド Ｉｌ－２バリアント及びその融合タンパク質
WO2023061005A1 (zh) * 2021-10-14 2023-04-20 徕特康(苏州)生物制药有限公司 新型抗体-细胞因子融合蛋白及其制备方法和用途
CN119451978A (zh) 2022-07-01 2025-02-14 神经基因治疗公司 Neo-2/15变体及其用于优先刺激T调节细胞的用途
EP4694916A1 (en) 2023-04-14 2026-02-18 SOTIO Biotech Inc. Engineered immune cells for treating cancer in combination with il-2/il-15 receptor ?? agonists
WO2025264955A1 (en) * 2024-06-21 2025-12-26 Tfc Therapeutics, Inc. Multispecific proteins and related methods

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE69133036T2 (de) * 1990-11-09 2003-02-06 Stephen D. Gillies Cytokine immunokonjugate
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
US5541087A (en) * 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US20030105294A1 (en) * 1998-02-25 2003-06-05 Stephen Gillies Enhancing the circulating half life of antibody-based fusion proteins
US6818418B1 (en) * 1998-12-10 2004-11-16 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
HUP0204475A2 (en) * 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
AU2002248571B2 (en) * 2001-03-07 2007-01-18 Merck Patent Gmbh Expression technology for proteins containing a hybrid isotype antibody moiety
WO2002079415A2 (en) * 2001-03-30 2002-10-10 Lexigen Pharmaceuticals Corp. Reducing the immunogenicity of fusion proteins
PT1383785E (pt) * 2001-05-03 2011-06-28 Merck Patent Gmbh Anticorpo recombinante específico de tumores e utilização deste
PT1454138E (pt) * 2001-12-04 2012-03-28 Merck Patent Gmbh Imunocitoquinas com seletividade modulada
US20040210035A1 (en) * 2002-01-30 2004-10-21 Straten Eivind Per Thor Survivin-derived peptides and use thereof
WO2004037284A1 (en) * 2002-10-22 2004-05-06 Sanofi Pasteur Limited Anti-cancer vaccines and high-dose cytokines as adjuvants
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
WO2004074437A2 (en) * 2003-02-14 2004-09-02 University Of Southern California Compositions and methods for cancer immunotherapy
DE602004027902D1 (de) * 2003-03-24 2010-08-12 Scripps Research Inst Dna-vakzine gegen tumorwachstum und anwendungsverfahren dafür
CU23297A1 (es) * 2004-11-16 2008-07-24 Ct De Inmunologa A Molecular Formulaciones inmunoterapã0/00uticas para la inducciã"n de autoanticuerpos bloqueadores de la uniã"n de interleucina-2 a su receptor. su uso en el tratamiento del cã ncer
GB0507696D0 (en) * 2005-04-15 2005-05-25 Novartis Ag Organic compounds

Similar Documents

Publication Publication Date Title
JP2009542592A5 (https=)
Ren et al. Selective delivery of low-affinity IL-2 to PD-1+ T cells rejuvenates antitumor immunity with reduced toxicity
Remark et al. The non–small cell lung cancer immune contexture. A major determinant of tumor characteristics and patient outcome
Burris et al. Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, in patients with advanced solid tumors
Van der Weyden et al. Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
ES2951650T3 (es) Uso de un anticuerpo anti-PD-1 junto con un anticuerpo anti-CD30 en el tratamiento del linfoma
EP3801769A1 (en) Combination therapy with chimeric antigen receptor (car) therapies
CN110461315A (zh) 使用与激酶抑制剂组合的嵌合抗原受体治疗和预防细胞因子释放综合征
CN110214150A (zh) 嵌合抗原受体和pd-1抑制剂的组合疗法
Ingles Garces et al. Building on the anti-PD1/PD-L1 backbone: combination immunotherapy for cancer
JP2023534808A (ja) 養子細胞療法のための標的共刺激を提供する受容体
JP2007500132A5 (https=)
JP2019521169A5 (https=)
CN113166778A (zh) T细胞修饰
EP3268387A1 (en) Compositions and methods for enhancing the efficacy of cancer therapy
Strickland et al. The immune landscape in BCR‐ABL negative myeloproliferative neoplasms: inflammation, infections and opportunities for immunotherapy
Leonard et al. Engineered cytokine/antibody fusion proteins improve delivery of IL-2 to pro-inflammatory cells and promote antitumor activity
Chandran et al. Single vs. combination immunotherapeutic strategies for glioma
Khan et al. Evolving concepts: immunity in oncology from targets to treatments
TW202342507A (zh) 抗ｓｔｅａｐ２嵌合抗原受體及其用途
Soler et al. Using chimeric antigen receptor T-cell therapy to fight glioblastoma multiforme: Past, present and future developments
Yi et al. Next-generation chimeric antigen receptor T-cells
Funauchi et al. Tumor cell‐expressed lipolysis‐stimulated lipoprotein receptor negatively regulates T‐cell function
Morchón-Araujo et al. Emerging immunotherapy targets in early drug development
Champiat et al. Nanrilkefusp alfa (SOT101), an IL-15 receptor βγ superagonist, as a single agent or with anti-PD-1 in patients with advanced cancers